ROBERT D. MASS, M.D.; ALAN P. VENOOK, M.D.; CHARLES A. LINKER, M.D.; ROBERT E. ZIPKIN, M.D.
To the editor: Pentoxifylline, a methylxanthine, has recently been advocated for the treatment of intermittent claudication caused by occlusive atherosclerotic vascular disease (1, 2). We report the cases of two patients with fatal aplastic anemia associated with the use of this drug.
Patient 1: An 80-year-old woman was hospitalized with pancytopenia. Three weeks before hospitalization she began treatment with pentoxifylline, 400 mg twice a day to promote healing of leg ulcers. During the next 2 weeks she developed progressive weakness, diffuse ecchymoses, and petechiae. The hematocrit was 26%; leukocyte count, 1700/mm3; and platelet count, 38 000. Other drugs included dyazide,
MASS RD, VENOOK AP, LINKER CA, ZIPKIN RE. Pentoxifylline and Aplastic Anemia. Ann Intern Med. ;107:427–428. doi: 10.7326/0003-4819-107-2-427_3
Download citation file:
Published: Ann Intern Med. 1987;107(3):427-428.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use